We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
Chemical Computing Group
CCG (Chemical Computing Group) is a leading supplier of software solutions for life sciences. With a proven track record in scientific innovation, CCG provides state-of-the-art applications in drug discovery to pharmaceutical, biotechnology and academic researchers. CCG headquarters are in Montreal (Canada), with support offices in North America, Europe and Asia.
Ubiquigent Ltd is a unique enabler of ubiquitin system and protein degradation-based drug discovery. Our commercial models include FFS and FTE access and features our Collaborative Drug Discovery programme. We provide access to the necessary expertise, Drug Discovery Services, Chemistry (novel deubiquitylase – DUB – enzyme-focussed libraries) and high quality Research Tools required to support our commercial and academic partners in pursuing ubiquitin system-focused drug discovery and protein degradation programmes, and in undertaking basic research.
LifeSensors generates reagents and drug discovery platforms which enable researchers to accurately and effectively assay the Ubiquitin Proteasome System. In addition to off-the-shelf products and kits, LifeSensors also partners with companies and researchers around the world to develop novel drug discovery assays. LifeSensors’ powerful technologies in conjunction with our expertise in the UPS, have enabled researchers to target and assay the undruggable targets.
Biodesy has developed a unique technology to detect structural changes in biological molecules, based on a phenomenon called second-harmonic generation (SHG), with applications in drug discovery and structural biology. Our sensitive, mass-independent platform can detect even weak affinity interactions, enabling a variety of approaches for challenging targets, from RNA to large protein complexes. In addition to our flagship product, the Delta™, we provide access to the technology through services to accomplish defined deliverables.
Bio-Techne brings together some of the most referenced brands in life science to provide innovative tools for Targeted Protein Degradation. Boston Biochem are world leaders in ubiquitin-proteasome system-related products, Tocris Bioscience are market leaders for research tool Degraders and Degrader building blocks while ProteinSimple provide automated platforms for detecting and quantifying protein degradation via Western Blot.
Together we are Bio-Techne. Find out how we can help you achieve your research goals.
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule targets Acute Myeloid Leukemia (in clinic Q2 2019) and our lead Protein Homeostatic Modulator (PHM™) will be in the clinic Q3 2020 for hematological malignancies.
Syngene International Ltd is an innovation focused global discovery, development and manufacturing organization providing integrated scientific services to pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Syngene’s innovative culture is driven by the passion of its 3500 strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, accelerate time to market and lower innovation costs. For more details, visit
MBL International Corporation
MBL International Corporation (MBLI) is a leading life science company focused on providing solutions for researchers in the life sciences, drug discovery and development and clinical diagnostics fields. Our special emphasis is on immunology, immuno-oncology, oncology and autoimmune disease areas. As a JSR Life Sciences Company, MBLI is committed to improve the probability of success, decrease timelines, and increase the efficacy of biologics-based therapies for the benefit of patients.